Last reviewed · How we verify
Fleet Enema
Fleet Enema is a marketed product under the Nova Scotia Health Authority, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-standing use for its indicated conditions. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Fleet Enema |
|---|---|
| Also known as | hyperosmolar enema |
| Sponsor | Nova Scotia Health Authority |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus. (PHASE1)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Dexamethasone for Ureteral STent Symptoms (DUSTS) (PHASE1, PHASE2)
- This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time (PHASE4)
- Open-Label Extension of EryDex Study IEDAT-04-2022 (PHASE3)
- Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity (NA)
- Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention (PHASE2)
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fleet Enema CI brief — competitive landscape report
- Fleet Enema updates RSS · CI watch RSS
- Nova Scotia Health Authority portfolio CI